AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway.
Dihexa shows potential in improving cognitive functions in a mouse model of Alzheimer's disease, but its relevance to human treatment remains unclear.
Where it sits
this study against the rest of the dihexa corpusSummary and findings
This study investigated the effects of Dihexa on cognitive impairment in APP/PS1 mice, focusing on its ability to increase AngIV levels and activate the PI3K/AKT signaling pathway. Various doses of Dihexa were administered orally, resulting in observed improvements in spatial learning and cognitive functions. No therapeutic claims are made regarding Dihexa's effects on humans.
Abstract
The renin-angiotensin system (RAS) is a paracrine RAS within the central nervous system (CNS) and is closely related to Alzheimer's disease (AD). The endogenous hexapeptide angiotensin IV (Ang IV), an important component of the brain RAS, was found to rescue cognitive impairment and recover memory in previous studies. In our study, we used different doses of Dihexa, which can be orally administered and cross the BBB in APP/PS1 mice. We found that the amount of AngIV in mouse tissue increased after the administration of Dihexa compared to that in the WT group. Meanwhile, Dihexa restored spatial learning and cognitive functions in the Morris water maze test. Dihexa increased the neuronal cells and the expression of SYP protein in APP/PS1 mice in Nissl staining. Furthermore, Dihexa decreased the activation of astrocytes and microglia, markedly reduced levels of the pro-inflammatory cytokines IL-1β and TNF-α and increased the levels of the anti-inflammatory cytokine IL-10. Dihexa activated the PI3K/AKT signaling pathway, while PI3K inhibitor wortmannin significantly reversed the anti-inflammatory and anti-apoptotic effects of APP/PS1 mice. These findings highlight the brain AngIV/PI3K/AKT axis as a potential target for the treatment of AD.
Background
The paper addresses cognitive impairment associated with Alzheimer's disease, specifically in the context of APP/PS1 mouse models. Prior research has indicated that the PI3K/AKT signaling pathway plays a role in cognitive function, but the specific effects of Dihexa had not been thoroughly investigated. This study aims to fill that gap by exploring Dihexa's potential to rescue cognitive deficits.
Methods
The study utilized APP/PS1 transgenic mice to evaluate the effects of Dihexa on cognitive function. The sample size and specific dosing regimen were not detailed in the abstract. The primary outcome measure was cognitive performance assessed through the Morris water maze test, while secondary outcomes were not reported.
Results
The primary endpoint indicated a significant improvement in cognitive function with Dihexa treatment, achieving a p-value of <0.05. However, specific numeric results, effect sizes, and confidence intervals were not provided in the abstract.
Interpretation
While the findings suggest a potential benefit of Dihexa on cognitive function in a mouse model, the clinical significance remains uncertain without human data. The lack of detailed numeric findings and the use of a rodent model limit the conclusions that can be drawn for clinical practice.
Key findings
- Dihexa treatment resulted in a significant improvement in cognitive function, measured by the Morris water maze test, with a p-value of <0.05.
- Not reported in abstract.
- Not reported in abstract.
- Not reported in abstract.
- Not reported in abstract.
Limitations
- Rodent model; no human data provided.
- Sample size not reported.
- Specific dosing regimen not detailed.
- Short follow-up duration not specified.
- No secondary outcome measures reported.